VOR Stock Analysis: Buy, Sell, or Hold?
VOR - Vor Biopharma Inc. Common Stock
$21.41
0.26 (1.23%)
▲
5d:
+10.13%
30d:
+3.98%
90d:
+54.58%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When VOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VOR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VOR is currently trading at $21.41, which is considered extended relative to its 30-day fair value range of $17.56 to $20.59.
Technical Outlook: Technically, VOR is in a strong uptrend. The price is approaching resistance at $21.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.88 (+79.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VOR is in a strong uptrend. The price is approaching resistance at $21.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VOR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.88 (+79.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.56 -
$20.59
Company Quality Score
55/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 79.1% below Wall St target ($37.88)
Trading Range Analysis
30-Day Trading Range
$17.56 -
$20.59
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.12
(14.6%)
Support & Resistance Levels
Support Level
$17.28
Resistance Level
$21.97
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.65
Wall Street Target
$37.88
(+79.1%)
Share & Embed Analysis
Last updated: August 03, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Ra Capital Management, L…
SELL
165150 shares
2026-04-22
Ra Capital Management, L…
SELL
171963 shares
2026-04-20
Ra Capital Management, L…
SELL
458411 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
